Relmada Therapeutics(NASDAQ) RLMD

Relmada Therapeutics, Inc. makes new medicines for cancer and brain disorders. It creates special delivery systems that help drugs work longer. These products help patients who have few other treatment options.

Fighting Cancer and Brain Disorders

• NDV-01: A long-acting treatment for non-muscle invasive bladder cancer (NMIBC) that delivers two chemotherapy drugs directly into the bladder for up to 10 days.
• Sepranolone: A synthetic version of a naturally occurring brain chemical designed to treat Prader-Willi syndrome (PWS) and Tourette syndrome (TS) by normalizing brain activity.
• Sustained-Release Technology: A delivery platform used in NDV-01 to maintain steady levels of medication at the tumor site while limiting side effects in the rest of the body.

Strategic Pivots and New Assets

• Acquired sepranolone from Asarina Pharma AB on Feb. 6, 2025, to enter the field of neurosteroid treatments for rare diseases.
• In-licensed NDV-01 from Trigone Pharma Ltd. on March 25, 2025, shifting the business focus toward oncology.
• Terminated the development of esmethadone and REL-P11 in 2025 following a strategic review of the product pipeline.
• Secured alignment with the U.S. Food and Drug Administration (FDA) in 2026 for the design of Phase 3 clinical trials for bladder cancer.

How Relmada Moves Faster

The company utilizes a 505(b)(2) regulatory pathway for its lead product, which allows it to rely on existing safety findings for approved drugs to accelerate development. It maintains an intellectual property portfolio with more than 50 patents and applications that could protect its drug formulations until 2047.

A Look at the Numbers

• Net loss was $31,966,100 for the six-month period ended June 30, 2026.
• Research and development expenses reached $16,481,634 for the six-month period ended June 30, 2026.
• Net proceeds from a private placement of common stock were approximately $150 million on March 11, 2026.
• Market capitalization was $777.6 million in the second quarter of 2026, up 3802.9% year over year.

The Path Forward

Relmada has transitioned from internal drug discovery to a strategy of acquiring and licensing external candidates for cancer and neurological conditions. This model focuses on using its clinical expertise to advance products that are already in middle or late stages of development.